Home>Topics>Stocks>Valeant Pharmaceuticals International

Valeant Pharmaceuticals International VRX

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. Ackman says he'll sue if Allergan buys Salix

      Headlines

      Tue, 23 Sep 2014

      through on its rumored acquisition of Salix Pharmaceuticals ( SLXP +5.5% ) without a shareholder vote. He claims that its attempts at acquisitions are desperate actions to thwart Valeant's ( VRX +0.7% ) takeover bid. Post your comment!

    2. Salix rumored to be in play again

      Headlines

      Tue, 23 Sep 2014

      Salix Pharmaceuticals (NASDAQ: SLXP ) is up 9% premarket on light volume. Allergan is rumored to be buying the firm in an all-cash transaction in an effort to fend off Valeant (NYSE: VRX ). Post your comment!

    3. Wall Street Breakfast: Treasury Tightens Rules To Fight Tax Inversions

      Headlines

      Tue, 23 Sep 2014

      By Wall Street Breakfast : Economy Under Treasury Secretary Jack Lew’s crackdown on inversions , the Treasury Department announced new tax rules late yesterday to deter U.S. companies from moving their domicile to countries with lower tax rates. The tax changes make it harder for companies to ...

    4. WSJ: Allergan closing in on Salix deal after turning down Actavis

      Headlines

      Mon, 22 Sep 2014

      turning down an offer from Actavis (NYSE: ACT ). The paper adds an Allerga/Salix deal, meant to thwart Valeant's (NYSE: VRX ) hostile bid for Allergan, could be announced "late this week or next." A source says Actavis is still interested in buying

    5. Allergan And Valeant: Lessons From The Go-Go Years

      Headlines

      Fri, 19 Sep 2014

      Conglomerates appeared on the scene, they claimed "synergies" and had skyrocketing "earnings" by doing hostile M&A. There are striking parallels to Valeant Pharmaceutical's (NYSE: VRX ) business model and the adoration of Complete Story »

    6. Foamix Pharmaceuticals IPO Merits Serious Investor Consideration

      Headlines

      Tue, 16 Sep 2014

      By Don Dion : Foamix Pharmaceuticals Ltd. (Pending: FOMX ), a specialty pharmaceutical company seeking to develop treatments for skin conditions, plans to raise $65.0 million in its upcoming IPO. The Rehovot, Israel-based firm will offer 5.9 million shares at an expected price range of $10-$12 per

    7. Wall Street Breakfast: Microsoft Announces Windows 9 Event Following Mojang Acquisition

      Headlines

      Tue, 16 Sep 2014

      By Wall Street Breakfast : Economy Hedge funds are cutting their long positions on cable , as the gap between "yes" and "no" votes for Scottish independence narrows. According to French asset management group Lyxor, investors on average have cut their positions from 5% of their net assets at the ...

    8. Special shareholder meeting scheduled for Dec. 18

      Headlines

      Tue, 16 Sep 2014

      Allergan (NYSE: AGN ) has reached an agreement with Bill Ackman's Pershing Square and Valeant (NYSE: VRX ) to hold a special shareholder meeting on the originally planned date, Dec. 18. After lining up investors who own a combined

    9. Ackman has 35% of AGN shareholders on board

      Headlines

      Thu, 11 Sep 2014

      AGN +0.1% ) shares lined up in support of the special shareholders meeting to install board members who favor Valeant's ( VRX +0.1% ) takeover bid. The 35% figure is significant because it preempts Allergan's efforts to exclude Pershing's 9

    10. Valeant: One Big Injection

      Headlines

      Tue, 9 Sep 2014

      2014] Valeant Pharmaceuticals (NYSE: VRX ) is a developer and marketer of a range ..... contact lenses. You may not have heard of VRX , but it owns Bausch & Lomb, the eye care ..... blockbuster drugs that might cure cancer, VRX has focused on dermatology (skin care such

    « Prev12345Next »
    Content Partners